Basic Information
RNALocate ID: | RLID:11003648 |
RNA Symbol: | hsa-miR-30c-2-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-30c-2-3p |
RNA ID: | miRBase:MIMAT0004550 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 23663360 |
Tissue/Cell Line: | Plasma |
Method: | Next-generation RNA sequencing |
Description: | Because the abundance of most miRNAs is low in the exosomes, we defined detectable miRNAs as those that had at least one sequence per million mappable miRNA reads. Accordingly, we detected a total of 593 known miRNAs in the 14 libraries. In each individual library, the number of detectable known miRNAs varied from 380 to 474 with an average of 419 [see Additional file 2]. Data are collected from Additional file 2: Read counts of the miRNAs detected in the 14 libraries (normalized to read number per million mappable miRNA seqeuences). |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01002590 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:11003647 | Exosome | B cell line (Raji)|Jurkat-derived T cell line (J77cl20) | 21505438 |
RLID:11003649 | Microvesicle | Seminal plasma | 23539611 |
RLID:11003650 | Microvesicle | Serum | 24797360 |
RLID-D:11000597 | Microvesicle | Fibroblasts|Mesenchymal stem cells | |
RLID-D:11001476 | Exosome | Breast milk|Cell lines|Epididymal epithelial cells|Osteoblast|Plasma|Primary glioblastoma neurosphere cells|Primary keratinocyte|Saliva|Serum|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-30c-2-3p | Oral squamous cell carcinoma | MNDR-E-MI-37184 |
MNDR | hsa-miR-30c-2-3p | Large cell neuroendocrine cancer | MNDR-E-MI-37185 |
MNDR | hsa-miR-30c-2-3p | Ovarian clear cell carcinoma | MNDR-E-MI-37186 |
MNDR | hsa-miR-30c-2-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-37187 |
MNDR | hsa-miR-30c-2-3p | Lymphoma | MNDR-E-MI-37188 |
MNDR | hsa-miR-30c-2-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-37189 |
MNDR | hsa-miR-30c-2-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-37190 |
MNDR | hsa-miR-30c-2-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-37191 |
MNDR | hsa-miR-30c-2-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-37192 |
MNDR | hsa-miR-30c-2-3p | Her2-receptor positive breast cancer | MNDR-E-MI-37193 |
MNDR | hsa-miR-30c-2-3p | Prostate cancer | MNDR-E-MI-37194 |
MNDR | hsa-miR-30c-2-3p | Gastric cancer | MNDR-E-MI-37195 |
MNDR | hsa-miR-30c-2-3p | Alzheimer disease | MNDR-E-MI-37196 |
MNDR | hsa-miR-30c-2-3p | Intracranial aneurysm | MNDR-E-MI-37197 |
MNDR | hsa-miR-30c-2-3p | Bladder cancer | MNDR-E-MI-37198 |
MNDR | hsa-miR-30c-2-3p | Esophageal carcinoma | MNDR-E-MI-37199 |
MNDR | hsa-miR-30c-2-3p | Parkinson disease | MNDR-E-MI-37200 |
MNDR | hsa-miR-30c-2-3p | Breast cancer | MNDR-E-MI-37201 |
MNDR | hsa-miR-30c-2-3p | Thyroid cancer | MNDR-E-MI-37202 |
MNDR | hsa-miR-30c-2-3p | Pancreatic cancer | MNDR-E-MI-37203 |
MNDR | hsa-miR-30c-2-3p | Melanoma | MNDR-E-MI-37204 |
MNDR | hsa-miR-30c-2-3p | Rectum adenocarcinoma | MNDR-E-MI-37205 |
MNDR | hsa-miR-30c-2-3p | Nephroblastoma | MNDR-E-MI-37206 |
MNDR | hsa-miR-30c-2-3p | Colon cancer | MNDR-E-MI-37207 |
MNDR | hsa-miR-30c-2-3p | Colon adenocarcinoma | MNDR-E-MI-37208 |
MNDR | hsa-miR-30c-2-3p | Familial ovarian cancer | MNDR-E-MI-37209 |
MNDR | hsa-miR-30c-2-3p | Prostate adenocarcinoma | MNDR-E-MI-37210 |
MNDR | hsa-miR-30c-2-3p | Kidney cancer | MNDR-E-MI-37211 |
MNDR | hsa-miR-30c-2-3p | Carcinoma ductal breast | MNDR-E-MI-37212 |
MNDR | hsa-miR-30c-2-3p | Glioma | MNDR-E-MI-37213 |
MNDR | hsa-miR-30c-2-3p | Chronic obstructive pulmonary disease | MNDR-E-MI-37214 |
MNDR | hsa-miR-30c-2-3p | Gastric adenocarcinoma | MNDR-E-MI-37215 |
MNDR | hsa-miR-30c-2-3p | Cervical squamous cell carcinoma | MNDR-E-MI-37216 |
MNDR | hsa-miR-30c-2-3p | Lung squamous cell carcinoma | MNDR-E-MI-37217 |
MNDR | hsa-miR-30c-2-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-37218 |
MNDR | hsa-miR-30c-2-3p | Lung adenocarcinoma | MNDR-E-MI-37219 |
MNDR | hsa-miR-30c-2-3p | Thyroid carcinoma | MNDR-E-MI-37220 |
MNDR | hsa-miR-30c-2-3p | Bladder urothelial carcinoma | MNDR-E-MI-37221 |
MNDR | hsa-miR-30c-2-3p | Pancreatic adenocarcinoma | MNDR-E-MI-37222 |
MNDR | hsa-miR-30c-2-3p | Carcinoma renal cell | MNDR-E-MI-37223 |
MNDR | hsa-miR-30c-2-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-37224 |
MNDR | hsa-miR-30c-2-3p | Renal clear cell carcinoma | MNDR-E-MI-37225 |
MNDR | hsa-miR-30c-2-3p | Biliary tract cancer | MNDR-E-MI-37226 |
MNDR | hsa-miR-30c-2-3p | Cholangiocarcinoma | MNDR-E-MI-37227 |
MNDR | hsa-miR-30c-2-3p | Lung small cell carcinoma | MNDR-E-MI-37228 |
MNDR | hsa-miR-30c-2-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-37229 |
MNDR | hsa-miR-30c-2-3p | Breast invasive carcinoma | MNDR-E-MI-37230 |
MNDR | hsa-miR-30c-2-3p | Progressive supranuclear palsy | MNDR-E-MI-37231 |
MNDR | hsa-miR-30c-2-3p | Hepatocellular carcinoma | MNDR-E-MI-37232 |
MNDR | hsa-miR-30c-2-3p | Familiar ovarian carcinoma | MNDR-E-MI-37233 |
MNDR | hsa-miR-30c-2-3p | Skin cutaneous melanoma | MNDR-E-MI-37234 |
MNDR | hsa-miR-30c-2-3p | Skin melanoma | MNDR-E-MI-37235 |
MNDR | hsa-miR-30c-2-3p | Colorectal cancer | MNDR-E-MI-37236 |
MNDR | hsa-miR-30c-2-3p | Nasopharynx carcinoma | MNDR-E-MI-37237 |
MNDR | hsa-miR-30c-2-3p | Nasopharyngeal cancer | MNDR-E-MI-37238 |
MNDR | hsa-miR-30c-2-3p | Intracranial hemorrhage hypertensive | MNDR-E-MI-37239 |
MNDR | hsa-miR-30c-2-3p | Breast cancer her3+ negative | MNDR-E-MI-37240 |
MNDR | hsa-miR-30c-2-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-37241 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ATF3 | Homo sapiens | RR00155508 |
TOP